Whole Body VibrationWBV/QOL/CIPNNCT07508527
Whole-Body Vibration on Balance, Risk of Falling and Quality of Life in Chemotherapy-Induced Peripheral Neuropathy
A study testing Whole Body Vibration and Traditional exercise in people with Whole Body Vibration and Chemotherapy Induced Peripheral Neuropathy (CIPN), run by Cairo University.
Trial summary
The goal of this clinical trial is to evaluate the efficacy of Whole-body vibration in improving postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy. Read more about this study
- Who is it for?
- Ages 30 to 60 years
- Conditions the study is for
- Whole Body Vibration, Chemotherapy Induced Peripheral Neuropathy (CIPN), Fall Risk, Fall Prevention
- What is being tested?
- Whole Body Vibration and Traditional exercise
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- 30 patients diagnosed with chemotherapy-induced peripheral neuropathy from both genders.
- Their ages will range from 30-60 years old.
- All patients included in this study will be on chemotherapy from at least one cycle as a treatment of malignant tumor.
- The patients will be mild to moderate neuropathy according to mTNS.
- They were medically stable.
Who cannot join
- History of other types of neuropathies (i.e., hereditry peripheral neuropathy associated with nutritional agents and paraneoplastic syndrome-related neuropathy…etc).
- Unstable medical condition during chemotherapy
- Patients who are starting new therapy or dose modification during study period
- Morbid obesity body mass index >40%
- History of non-surgically repaired nerve compression injuries such as carpal tunnel, brachial plexopathy, spinal stenosis, and spinal nerve root compression
- History of central nervous system primary or metastatic malignancy.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Bothina Sayed Mohamed Sayed, Bachelor's Degree contact
About this study
Official title: Effect of Whole Body Vibration on Balance, Risk of Falling, and Quality of Life in Patients With Chemotherapy Induced Peripheral Neuropathy
The goal of this clinical trial is to evaluate the efficacy of Whole-body vibration in improving postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy. The main questions it aims to answer are:
Does Whole-body vibration have a significant effect on postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy?
Read more
Researchers will compare whole body vibration in addition to traditional exercise to traditional exercise alone to see if Whole-body vibration have a significant effect on postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy.
Participants will:
- age between 30-60 years old.
- be on chemotherapy for at least one cycle as a treatment of malignant tumors with peripheral neuropathy.
- have mild to moderate neuropathy according to mTNS.
- be assigned randomly into two equal groups (control group (A) and study group (B)).
- Take three sessions per week for eight weeks.
- The control group (A) will be treated by selected physical therapy treatment (Strength resistive training, Stretching \& flexibility, Balance training)
- The study group (B) will be treated with selected physical therapy treatment in addition to whole-body vibration therapy.
Read the detailed description
Chemotherapy-induced peripheral neuropathy (CIPN) is a persistent cancer treatment-related side effect that negatively impacts physical functioning, falls, and quality of life. CIPN may lead to muscle weakness, loss of ankle reflexes, and impairment in balance, coordination, and gait control, which significantly increase the risk of falling and sustaining fall-related injuries. Risk of fall in cancer patients occur due to multimodal causes that occur either due to cancer itself or anti- cancer drugs, some of the side-effects that may have the upper hand in increasing risk of fall are sarcopenia, chemotherapy induced peripheral neuropathy, decrease in exercise capacity and muscle strength, decrease balance function, and physical frailty. For cancer survivors, falling and the combined effects of these risk factors have a detrimental influence on felt well-being and a substantial potential reduction in quality of life. Falls also impose significant burdens psychologically (e.g., developing anxiety and fear of falling) and economically (e.g., incurring large medical costs). Furthermore, the loss of independence following a fall and the fear of falling again can have a negative impact on a patient's quality of life. Whole-body vibration emerged as an alternative to improve neuromuscular functions and fall risk in the physical therapy field. The transmission of such mechanical vibrations to the human body causes the tonic vibration reflex (TVR), a complex spinal and supraspinal neurophysiological reaction. The TVR increases muscle activation and improves functional performance.It causes the motor units to be activated, which results in neuromuscular facilitation. This improves the patient's total functional activity and their static and dynamic balance. All these consequences are equivalent to engaging in any cumbersome exercise or difficult activity, which is impractical for these people.
This study aims to investigate the effect of Whole-body vibration on postural control, risk of falling and quality of life in patients with chemotherapy-induced peripheral neuropathy.
Thirty patients from both sexes were diagnosed with cancer and chemotherapy-induced peripheral neuropathy. They will be selected from centre of Clinical Oncology and Nuclear Medicine at El-Kasr Al-Aini Hospitals.Their ages will range from 30 to 60 years old. All patients who will be included will be on chemotherapy for at least one cycle as a treatment of malignant tumors with peripheral neuropathy. The patients will have mild to moderate neuropathy according to mTNS. All Patients should understand verbal instructions and follow the instructor. The selected patients will be assigned randomly into two equal groups (control group (A) and study group (B)).
- Conditions
- Whole Body Vibration, Chemotherapy Induced Peripheral Neuropathy (CIPN), Fall Risk, Fall Prevention, Balance, Quality of Life
- Being tested
- Whole Body Vibration, Traditional exercise
- Keywords
- WBV, Whole body vibration, CIPN, Chemotherapy induced peripheral neuropathy, Balance, Risk of fall, falling, postural control, fall, QOL, Quality of life
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whole Body VibrationDevice
Also called Whole-Body Vibration, WBV
15 min of Whole-body vibration therapy 3 sessions per week for 8 weeks, as follow: 24
- Duration: about 15 minutes per session
- Vibration Frequency: 18-40 Hz (starting at lower frequency and progressing)
- Position: Standing on the platform with slight knee flexion to activate muscles, progressing to squats and dynamic movements over time. The patient may start standing.
- Progression Plan:
- Weeks 1-2: Low frequency (18-25 Hz) for short intervals
- Weeks 3-5: Increase frequency to (25-35 Hz) with longer intervals
- Weeks 6-8: Progress to higher frequency (35-40 Hz) with the introduction of additional balance exercises while on the platform (e.g., squats, heel raises).
Traditional exerciseOther
-Strength resistive training: Core strengthening, Squat \& set up, sit to stand exercise, calf raises \& squats, Seated leg ex, Straight leg raising exercise, clamshell, Dorsi flexion exercise, Quad set
-Stretching \& flexibility: Stretch for lower limb (Hamstring, Calf)
- Balance training: Single leg stance (Stable surface then unstable one), Gait training with obstacles \& alternating speed \& different directions (side steps, steps over cones), Balane board.
| Study group | Role | What they receive |
|---|---|---|
| Control Group (Group A) | Active comparator | Group A (Control Group): Patients will receive selected physical therapy treatment, 3 sessions per week for 8 weeks. The session will contain:
* Strength resistance training:
Core strengthening, Squat \& set up, sit to stand exercise, calf raises \& squats, Seated leg ex, Straight leg raising exercise, clamshell, Dorsi flexion exercise, Quad set - Stretching \& flexibility: Stretch for lower limb (Hamstring, Calf)
- Balance training: Single leg stance (Stable surface then unstable one), Gait training with obstacles \& alternating speed \& different directions (side steps, steps over cones), Balane board. Receives: Other: Traditional exercise |
| Study Group (Group B) | Experimental | Group B (Study Group): Patients will receive the same selected physical therapy as in group (A) in addition to 15 min of Whole-body vibration therapy 3 sessions per week for 8 weeks, as follow:
* Duration: about 15 minutes per session
* Vibration Frequency: 18-40 Hz (starting at lower frequency and progressing)
* Position: Standing on the platform with slight knee flexion to activate muscles, progressing to squats and dynamic movements over time. The patient may start standing.
* Progression Plan:
* Weeks 1-2: Low frequency (18-25 Hz) for short intervals
* Weeks 3-5: Increase frequency to (25-35 Hz) with longer intervals
* Weeks 6-8: Progress to higher frequency (35-40 Hz) with the introduction of additional balance exercises while on the platform (e.g., squats, heel raises). Receives: Device: Whole Body Vibration; Other: Traditional exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Risk of fall
It will be measured by Falls Efficacy Scale International (FES-I):
FES-I consists of 16 items, each rated on a 4-point Likert scale:
- = Not at all concerned
- = Somewhat concerned
- = Fairly concerned
- = Very concerned
Scoring and Interpretation:
Minimum score = 16 (no concern about falling). Maximum score = 64 (high concern about falling). 16-19 → Low concern about falling. 20-27 → Moderate concern. 28-64 → High concern, associated with increased fall risk and activity avoidance.
Measured: From enrollment to the end of treatment at 8 weeks
Quality of life (QOL)
The FACT-GOG-NTX is a combination of the FACT-G (core cancer QoL questionnaire, 27 items) and a specific neurotoxicity subscale (NTX, 11 items).
- FACT-G (27 items, Core QoL Measure):
- Physical Well-being (PWB) (7 items).
- Social/Family Well-being (SWB) (7 items) .
- Emotional Well-being (EWB) (6 items).
- Functional Well-being (FWB) (7 items).
- NTX Subscale (11 items, Chemotherapy-Induced Neuropathy Symptoms) Sensory Symptoms Motor Symptoms . Autonomic Symptoms. Interference with Daily Activities.
Scoring of the FACT-GOG-NTX:
Items are rated on a 5-point Likert scale:
0 = Not at all
- = A little bit
- = Somewhat
- = Quite a bit
- = Very much Higher scores in the FACT-G core scales = Better QoL. Higher NTX subscale scores = Worse neurotoxicity symptoms.
Measured: From enrollment to the end of treatment at 8 weeks
Balance
It will be measured by Berg Balance Scale (BBS)
Berg Balance Scale(BBS):
BBS consists of 14 functional tasks, each scored on a five-point ordinal scale (0-4), with a maximum total score of 56. Higher scores indicate better balance and a lower risk of falls.(Muir et al., 2008) Appendix III
The tasks include:
Static balance tasks (e.g., standing unsupported, sitting balance) Dynamic balance tasks (e.g., reaching forward, turning 360°, standing on one leg) Transfers and weight shifts (e.g., sit-to-stand, standing with eyes closed)
Scores for Fall Risk:
0-20: High fall risk 21-40: Moderate fall risk 41-56: Low fall risk
Measured: From enrollment to the end of treatment at 8 weeks
Secondary outcomes (1)
Functional mobility
It will be measured by Time Up \& Go test (TUG) The Timed Up and Go (TUG) test is a widely used functional mobility and fall risk assessment tool.
The test measures the time (in seconds) it takes for a person to:
- Stand up from a standard chair (seat height ~46 cm).
- Walk 3 meters (10 feet) at a comfortable pace.
- Turn around 180 degrees.
- Walk back to the chair.
- Sit down again. The entire test is timed in seconds, with shorter times indicating better functional mobility.
- Scoring:
- < 10 sec → Normal mobility.
- 11-20 sec → Normal for elderly or disabled individuals but indicates some mobility challenges.
- 20 sec → Increased fall risk and functional impairment, i.e. poor mobility or might be due to poor mentality.
- 30 sec → High fall risk and significant mobility impairment.
Measured: From enrollment to the end of treatment at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2026
- Study startApr 2026 (estimated)
- Primary completionApr 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Whole Body VibrationStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Controlled Trail
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bothina Sayed Mohamed Sayed, Cairo University
- Investigators
- Bothina Sayed Mohamed, Bachelor's Degree, Principal investigator, Physical Therapist at Department of clinical oncology and nuclear medicine, Cairo university Hospitals (Kasr El-Einy); Bachelor's Degree from Faculty of Physical Therapy, Cairo UniversityMohamed Abd El-Rahman Hassan, Professor of Clinical Oncology, Study director, Professor of Clinical Oncology, Department of clinical oncology and nuclear medicine, Faculty of Medicine, Kasr El-Einy, Cairo University.Nahed Ahmed Salem, Professor of Physical Therapy, Study chair, Professor of Physical Therapy for Neurology and Neurosurgery, Faculty of Physical Therapy, Cairo UniversityMohamed Helayel Marzouk, Lecture of Physical Therapy, Study director, Lecture of Physical Therapy for Neurology and Neurosurgery, Faculty of Physical Therapy, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07508527
- Sponsor's protocol ID
- P.T.REC/012/005790
- Acronym
- WBV/QOL/CIPN
- Status last verified
- Mar 2026
- First submitted
- 16 Mar 2026
- Last updated
- 2 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Whole Body Vibration on Balance, Risk of Falling, and Quality of Life in Patients With Chemotherapy Induced Peripheral Neuropathy
- ClinicalTrials.gov ID
- NCT07508527
- Acronym / sponsor ID
- WBV/QOL/CIPN / P.T.REC/012/005790
- Conditions
- Whole Body Vibration, Chemotherapy Induced Peripheral Neuropathy (CIPN), Fall Risk, Fall Prevention, Balance, Quality of Life
- Keywords
- WBV, Whole body vibration, CIPN, Chemotherapy induced peripheral neuropathy, Balance, Risk of fall, falling, postural control
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 2 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the efficacy of Whole-body vibration in improving postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy. The main questions it aims to answer are:
Does Whole-body vibration have a significant effect on postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy?
Researchers will compare whole body vibration in addition to traditional exercise to traditional exercise alone to see if Whole-body vibration have a significant effect on postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy.
Participants will:
- age between 30-60 years old.
- be on chemotherapy for at least one cycle as a treatment of malignant tumors with peripheral neuropathy.
- have mild to moderate neuropathy according to mTNS.
- be assigned randomly into two equal groups (control group (A) and study group (B)).
- Take three sessions per week for eight weeks.
- The control group (A) will be treated by selected physical therapy treatment (Strength resistive training, Stretching \& flexibility, Balance training)
- The study group (B) will be treated with selected physical therapy treatment in addition to whole-body vibration therapy.
Detailed description
Chemotherapy-induced peripheral neuropathy (CIPN) is a persistent cancer treatment-related side effect that negatively impacts physical functioning, falls, and quality of life. CIPN may lead to muscle weakness, loss of ankle reflexes, and impairment in balance, coordination, and gait control, which significantly increase the risk of falling and sustaining fall-related injuries. Risk of fall in cancer patients occur due to multimodal causes that occur either due to cancer itself or anti- cancer drugs, some of the side-effects that may have the upper hand in increasing risk of fall are sarcopenia, chemotherapy induced peripheral neuropathy, decrease in exercise capacity and muscle strength, decrease balance function, and physical frailty. For cancer survivors, falling and the combined effects of these risk factors have a detrimental influence on felt well-being and a substantial potential reduction in quality of life. Falls also impose significant burdens psychologically (e.g., developing anxiety and fear of falling) and economically (e.g., incurring large medical costs). Furthermore, the loss of independence following a fall and the fear of falling again can have a negative impact on a patient's quality of life. Whole-body vibration emerged as an alternative to improve neuromuscular functions and fall risk in the physical therapy field. The transmission of such mechanical vibrations to the human body causes the tonic vibration reflex (TVR), a complex spinal and supraspinal neurophysiological reaction. The TVR increases muscle activation and improves functional performance.It causes the motor units to be activated, which results in neuromuscular facilitation. This improves the patient's total functional activity and their static and dynamic balance. All these consequences are equivalent to engaging in any cumbersome exercise or difficult activity, which is impractical for these people.
This study aims to investigate the effect of Whole-body vibration on postural control, risk of falling and quality of life in patients with chemotherapy-induced peripheral neuropathy.
Thirty patients from both sexes were diagnosed with cancer and chemotherapy-induced peripheral neuropathy. They will be selected from centre of Clinical Oncology and Nuclear Medicine at El-Kasr Al-Aini Hospitals.Their ages will range from 30 to 60 years old. All patients who will be included will be on chemotherapy for at least one cycle as a treatment of malignant tumors with peripheral neuropathy. The patients will have mild to moderate neuropathy according to mTNS. All Patients should understand verbal instructions and follow the instructor. The selected patients will be assigned randomly into two equal groups (control group (A) and study group (B)).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Randomized Controlled Trail
| Arm | Type | Receives |
|---|---|---|
| Control Group (Group A) | Active comparator | Other: Traditional exerciseGroup A (Control Group): Patients will receive selected physical therapy treatment, 3 sessions per week for 8 weeks. The session will contain: * Strength resistance training: Core strengthening, Squat \& set up, sit to stand exercise, calf raises \& squats, Seated leg ex, Straight leg raising exercise, clamshell, Dorsi flexion exercise, Quad set - Stretching \& flexibility: Stretch for lower limb (Hamstring, Calf) - Balance training: Single leg stance (Stable surface then unstable one), Gait training with obstacles \& alternating speed \& different directions (side steps, steps over cones), Balane board. |
| Study Group (Group B) | Experimental | Device: Whole Body Vibration, Other: Traditional exerciseGroup B (Study Group): Patients will receive the same selected physical therapy as in group (A) in addition to 15 min of Whole-body vibration therapy 3 sessions per week for 8 weeks, as follow: * Duration: about 15 minutes per session * Vibration Frequency: 18-40 Hz (starting at lower frequency and progressing) * Position: Standing on the platform with slight knee flexion to activate muscles, progressing to squats and dynamic movements over time. The patient may start standing. * Progression Plan: * Weeks 1-2: Low frequency (18-25 Hz) for short intervals * Weeks 3-5: Increase frequency to (25-35 Hz) with longer intervals * Weeks 6-8: Progress to higher frequency (35-40 Hz) with the introduction of additional balance exercises while on the platform (e.g., squats, heel raises). |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- 30 patients diagnosed with chemotherapy-induced peripheral neuropathy from both genders.
- Their ages will range from 30-60 years old.
- All patients included in this study will be on chemotherapy from at least one cycle as a treatment of malignant tumor.
- The patients will be mild to moderate neuropathy according to mTNS.
- They were medically stable.
Key exclusion criteria (6 listed)
- History of other types of neuropathies (i.e., hereditry peripheral neuropathy associated with nutritional agents and paraneoplastic syndrome-related neuropathy…etc).
- Unstable medical condition during chemotherapy
- Patients who are starting new therapy or dose modification during study period
- Morbid obesity body mass index >40%
- History of non-surgically repaired nerve compression injuries such as carpal tunnel, brachial plexopathy, spinal stenosis, and spinal nerve root compression
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Whole Body VibrationAlso: Whole-Body Vibration, WBV15 min of Whole-body vibration therapy 3 sessions per week for 8 weeks, as follow: 24 * Duration: about 15 minutes per session * Vibration Frequency: 18-40 Hz (starting at lower frequency and progressing) * Position: Standing on the platform with slight knee flexion to activate muscles, progressing to squats and dynamic movements over time. The patient may start standing. * Progression Plan: * Weeks 1-2: Low frequency (18-25 Hz) for short intervals * Weeks 3-5: Increase frequency to (25-35 Hz) with longer intervals * Weeks 6-8: Progress to higher frequency (35-40 Hz) with the introduction of additional balance exercises while on the platform (e.g., squats, heel raises). | Device | Study Group (Group B) |
| Traditional exercise-Strength resistive training: Core strengthening, Squat \& set up, sit to stand exercise, calf raises \& squats, Seated leg ex, Straight leg raising exercise, clamshell, Dorsi flexion exercise, Quad set -Stretching \& flexibility: Stretch for lower limb (Hamstring, Calf) - Balance training: Single leg stance (Stable surface then unstable one), Gait training with obstacles \& alternating speed \& different directions (side steps, steps over cones), Balane board. | Other | Control Group (Group A), Study Group (Group B) |
Primary outcome
Risk of fall
Time frame: From enrollment to the end of treatment at 8 weeks
It will be measured by Falls Efficacy Scale International (FES-I): FES-I consists of 16 items, each rated on a 4-point Likert scale: 1. = Not at all concerned 2. = Somewhat concerned 3. = Fairly concerned 4. = Very concerned Scoring and Interpretation: Minimum score = 16 (no concern about falling). Maximum score = 64 (high concern about falling). 16-19 → Low concern about falling. 20-27 → Moderate concern. 28-64 → High concern, associated with increased fall risk and activity avoidance.
Quality of life (QOL)
Time frame: From enrollment to the end of treatment at 8 weeks
The FACT-GOG-NTX is a combination of the FACT-G (core cancer QoL questionnaire, 27 items) and a specific neurotoxicity subscale (NTX, 11 items). 1. FACT-G (27 items, Core QoL Measure): 1. Physical Well-being (PWB) (7 items). 2. Social/Family Well-being (SWB) (7 items) . 3. Emotional Well-being (EWB) (6 items). 4. Functional Well-being (FWB) (7 items). 2. NTX Subscale (11 items, Chemotherapy-Induced Neuropathy Symptoms) Sensory Symptoms Motor Symptoms . Autonomic Symptoms. Interference with Daily Activities. Scoring of the FACT-GOG-NTX: Items are rated on a 5-point Likert scale: 0 = Not at all 1. = A little bit 2. = Somewhat 3. = Quite a bit 4. = Very much Higher scores in the FACT-G core scales = Better QoL. Higher NTX subscale scores = Worse neurotoxicity symptoms.
Balance
Time frame: From enrollment to the end of treatment at 8 weeks
It will be measured by Berg Balance Scale (BBS) Berg Balance Scale(BBS): BBS consists of 14 functional tasks, each scored on a five-point ordinal scale (0-4), with a maximum total score of 56. Higher scores indicate better balance and a lower risk of falls.(Muir et al., 2008) Appendix III The tasks include: Static balance tasks (e.g., standing unsupported, sitting balance) Dynamic balance tasks (e.g., reaching forward, turning 360°, standing on one leg) Transfers and weight shifts (e.g., sit-to-stand, standing with eyes closed) Scores for Fall Risk: 0-20: High fall risk 21-40: Moderate fall risk 41-56: Low fall risk
1 secondary outcome
Functional mobility
Time frame: From enrollment to the end of treatment at 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Whole Body Vibration
Not yet recruiting
Effects of Whole-Body Vibration and Cervical Stabilization With Core Stabilization in Young Adults With Non-Specific Low Back Pain
Nonspecific Low Back Pain
RecruitingPhase 4
Improving Morning Strength and Cognitive Performance Using Caffeine or Whole-body Vibration.
Vibration Therapy, Caffeine
Not yet recruiting
Stair Biomechanics and Vibration Study After ACLR
Anterior Cruciate Ligament Reconstruction (ACLR), Anterior Cruciate Ligament Injury
Active, not recruiting
Hypopressive-Core Stabilization With and Without Whole-Body Vibration in Postpartum Pelvic Girdle Pain
Postpartum Pelvic Girdle Pain
Active, not recruiting
Health Benefits of Whole-body Vibration
Whole-body Vibration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bothina Sayed Mohamed Sayed, Bachelor's Degree contact
Bothina Sayed Mohamed, Bachelor's Degree principal investigator
Physical Therapist at Department of clinical oncology and nuclear medicine, Cairo university Hospitals (Kasr El-Einy); Bachelor's Degree from Faculty of Physical Therapy, Cairo University
Mohamed Abd El-Rahman Hassan, Professor of Clinical Oncology study director
Professor of Clinical Oncology, Department of clinical oncology and nuclear medicine, Faculty of Medicine, Kasr El-Einy, Cairo University.
Nahed Ahmed Salem, Professor of Physical Therapy study chair
Professor of Physical Therapy for Neurology and Neurosurgery, Faculty of Physical Therapy, Cairo University
Questions about this trial
What is this clinical trial studying?
A study testing Whole Body Vibration and Traditional exercise in people with Whole Body Vibration and Chemotherapy Induced Peripheral Neuropathy (CIPN), run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bothina Sayed Mohamed Sayed, Bachelor's Degree (01016108245 ext. 01143077366, 1300153@st.pt.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Risk of fall (time frame: From enrollment to the end of treatment at 8 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.